XERS - Xeris Biopharma Holdings, Inc.
About Xeris Biopharma Holdings, Inc. (https://www.xerispharma.com)
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| John Shannon | Chief Executive Officer & Director | 1962 | $1,355,969 USD |
| Kevin McCulloch | President & Chief Operating Officer | 1964 | $913,527 USD |
| Beth Hecht | Chief Legal Officer & Corporate Secretary | 1964 | $817,367 USD |
| Steven Pieper | Chief Financial Officer | 1977 | $796,183 USD |
| Anh Nguyen | Chief Medical Officer | 1975 | $653,703 USD |
| Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | – | – |
| Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | – | – |
| Kendal Korte | Senior Vice President of Human Resources | – | – |